{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:08:13Z","timestamp":1791857293723,"version":"4.3.4"},"reference-count":28,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>BRCA1 and BRCA2 are the most important breast and ovarian cancer susceptibility genes. Biallelic mutations in BRCA2 can lead to Fanconi anemia and predisposition to cancers, whereas biallelic BRCA1 mutations have not been confirmed, presumably because one wild-type BRCA1 allele is required during embryogenesis. This study describes an individual who was diagnosed with ovarian carcinoma at age 28 and found to have one allele with a deleterious mutation in BRCA1, c.2457delC (p.Asp821Ilefs*25), and a second allele with a variant of unknown significance in BRCA1, c.5207T&amp;gt;C (p.Val1736Ala). Medical records revealed short stature, microcephaly, developmental delay, and significant toxicity from chemotherapy. BRCA1 p.Val1736Ala cosegregated with cancer in multiple families, associated tumors showed loss of wild-type BRCA1, and BRCA1 p.Val1736Ala showed reduced DNA damage localization. These findings represent the first validated example of biallelic deleterious human BRCA1 mutations and have implications for the interpretation of genetic test results.<\/jats:p>\n                  <jats:p>Significance: Accurate assessment of genetic testing data for BRCA1 mutations is essential for clinical monitoring and treatment strategies. Here, we report the first validated example of an individual with biallelic BRCA1 mutations, early-onset ovarian cancer, and clinically significant hypersensitivity to chemotherapy. Cancer Discov; 3(4); 399\u2013405. \u00a92012 AACR.<\/jats:p>\n                  <jats:p>See related commentary by D'Andrea, p. 376<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 363<\/jats:p>","DOI":"10.1158\/2159-8290.cd-12-0421","type":"journal-article","created":{"date-parts":[[2012,12,26]],"date-time":"2012-12-26T20:47:16Z","timestamp":1356554836000},"page":"399-405","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Biallelic Deleterious\n                    <i>BRCA1<\/i>\n                    Mutations in a Woman with Early-Onset Ovarian Cancer"],"prefix":"10.1158","volume":"3","author":[{"given":"Susan M.","family":"Domchek","sequence":"first","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangbo","family":"Tang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Stopfer","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana R.","family":"Lilli","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Hamel","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tischkowitz","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro N.A.","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy E.","family":"Messick","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn","family":"Powers","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Yonker","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus J.","family":"Couch","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Goldgar","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Rosemarie","family":"Davidson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Nathanson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"},{"name":"Authors' Affiliations: 1Abramson Cancer Center, Departments of 2Medicine, 3Cancer Biology, and 4Pathology and Laboratory Medicine, 5Basser Research Center for BRCA1\/2, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; 6Vironika, Philadelphia, Pennsylvania; 7Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; 8Program in Cancer Genetics, Departments of Oncology and Human Genetics, and 9Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 10Department of Medical Genetics, University of Cambridge, Cambridge; and 11Ferguson Smith Centre for Clinical Genetics, Yorkhill, Glasgow, United Kingdom; 12Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; 13Cancer Genetic Risk Assessment Program, Bryan Hemming Cancer Care Center, San Francisco, California; 14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 15Huntsman Cancer Institute and Department of"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2013,4,10]]},"reference":[{"key":"2022060623255108700_bib1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"2022060623255108700_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.1073834","article-title":"Biallelic inactivation of BRCA2 in Fanconi anemia","volume":"297","author":"Howlett","year":"2002","journal-title":"Science"},{"key":"2022060623255108700_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ng1942","article-title":"Fanconi anemia is associated with a defect in the BRCA2 partner PALB2","volume":"39","author":"Xia","year":"2007","journal-title":"Nat Genet"},{"key":"2022060623255108700_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ng1947","article-title":"Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer","volume":"39","author":"Reid","year":"2007","journal-title":"Nat Genet"},{"key":"2022060623255108700_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ng0207-142","article-title":"Fanconi anemia and breast cancer susceptibility","volume":"39","author":"Patel","year":"2007","journal-title":"Nat Genet"},{"key":"2022060623255108700_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccr.2005.08.004","article-title":"BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ","volume":"8","author":"Litman","year":"2005","journal-title":"Cancer Cell"},{"key":"2022060623255108700_bib7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/ng1625","article-title":"The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J","volume":"37","author":"Levitus","year":"2005","journal-title":"Nat Genet"},{"key":"2022060623255108700_bib8","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1038\/sj.onc.1209871","article-title":"Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects","volume":"25","author":"Evers","year":"2006","journal-title":"Oncogene"},{"key":"2022060623255108700_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.1209909","article-title":"BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity","volume":"334","author":"Shakya","year":"2011","journal-title":"Science"},{"key":"2022060623255108700_bib10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"2022060623255108700_bib11","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1158\/1078-0432.CCR-06-1246","article-title":"Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom","volume":"12","author":"Shanley","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022060623255108700_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"2022060623255108700_bib13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1086\/378100","article-title":"A full-likelihood method for the evaluation of causality of sequence variants from family data","volume":"73","author":"Thompson","year":"2003","journal-title":"Am J Hum Genet"},{"key":"2022060623255108700_bib14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"2022060623255108700_bib15","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.cell.2010.04.038","article-title":"ATM-dependent chromatin changes silence transcription in cis to DNA double-strand breaks","volume":"141","author":"Shanbhag","year":"2010","journal-title":"Cell"},{"key":"2022060623255108700_bib16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/375541b0","article-title":"A human BRCA1 gene knockout","volume":"375","author":"Boyd","year":"1995","journal-title":"Nature"},{"key":"2022060623255108700_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1054\/bjoc.1999.0984","article-title":"Evidence of a founder BRCA1 mutation in Scotland","volume":"82","author":"Liede","year":"2000","journal-title":"Br J Cancer"},{"key":"2022060623255108700_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/gcc.1122","article-title":"Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing","volume":"31","author":"Kuschel","year":"2001","journal-title":"Genes Chrom Cancer"},{"key":"2022060623255108700_bib19","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1086\/302671","article-title":"The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study","volume":"65","author":"Stratton","year":"1999","journal-title":"Am J Hum Genet"},{"key":"2022060623255108700_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/2159-8290.CD-12-0221","article-title":"Mechanisms of BRCA1 tumor suppression","volume":"2","author":"Silver","year":"2012","journal-title":"Cancer Discov"},{"key":"2022060623255108700_bib21","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1128\/MCB.21.12.4005-4015.2001","article-title":"Impaired DNA damage response in cells expressing an exon 11-deleted murine Brca1 variant that localizes to nuclear foci","volume":"21","author":"Huber","year":"2001","journal-title":"Mol Cell Biol"},{"key":"2022060623255108700_bib22","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1101\/gad.879201","article-title":"Tumorigenesis in mice carrying a truncating Brca1 mutation","volume":"15","author":"Ludwig","year":"2001","journal-title":"Gen Dev"},{"key":"2022060623255108700_bib23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/90108","article-title":"Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis","volume":"28","author":"Xu","year":"2001","journal-title":"Nat Genet"},{"key":"2022060623255108700_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/MCB.17.1.444","article-title":"Localization of BRCA1 and a splice variant identifies the nuclear localization signal","volume":"17","author":"Thakur","year":"1997","journal-title":"Mol Cell Biol"},{"key":"2022060623255108700_bib25","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1158\/0008-5472.CAN-09-4563","article-title":"Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays","volume":"70","author":"Lee","year":"2010","journal-title":"Cancer Res"},{"key":"2022060623255108700_bib26","doi-asserted-by":"crossref","first-page":"20080","DOI":"10.1074\/jbc.M109.088922","article-title":"Toward classification of BRCA1 missense variants using a biophysical approach","volume":"285","author":"Rowling","year":"2010","journal-title":"J Biol Chem"},{"key":"2022060623255108700_bib27","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1200\/JCO.2008.17.8228","article-title":"Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance","volume":"26","author":"Spearman","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060623255108700_bib28","doi-asserted-by":"crossref","first-page":"10096","DOI":"10.1158\/0008-5472.CAN-05-1241","article-title":"Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations","volume":"65","author":"Judkins","year":"2005","journal-title":"Cancer Res"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/3\/4\/399\/1817960\/399.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/3\/4\/399\/1817960\/399.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T19:26:07Z","timestamp":1654543567000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/3\/4\/399\/4072\/Biallelic-Deleterious-BRCA1-Mutations-in-a-Woman"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,1]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,10]]},"published-print":{"date-parts":[[2013,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-12-0421","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22529727.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529730.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529733.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546027","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546027.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529733","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529730","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529739","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529736","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529739.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529727","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529736.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,1]]}}}